Skip to the content
Please enable JavaScript in your browser to complete this form.
We would greatly appreciate it if you could take a few moments to answer the following questions. Your comments will help us improve the quality of our future events. We look forward to receiving your feedback.
Please rate your experience of the webinar and answer the accompanying questions.
PRESENTATIONS AND DISCUSSIONS
1. Please rate the following presentations and sessions. (5=Excellent, 4=Good, 3=Average, 2=Below average, 1=Poor)
Overall Webinar Content
Overall Webinar Content
5
4
3
2
1
5
Item #1 5
4
Item #1 4
3
Item #1 3
2
Item #1 2
1
Item #1 1
Current global treatment guidelines for R/R DLBCL
Dr Junichiro Yuda
Current global treatment guidelines for R/R DLBCL
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
Management of CRS associated with evolving treatments –Guidelines/protocol in Hong Kong
Prof Eric Wai Choi Tse
Management of CRS associated with evolving treatments –Guidelines/protocol in Hong Kong
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
Management of CRS/ICANS associated with evolving treatments– Guidelines/protocol in Singapore
Dr Chen Yunxin
Management of CRS/ICANS associated with evolving treatments– Guidelines/protocol in Singapore
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
Panel discussion/Q&A Session
Panel discussion/Q&A Session
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
2. Please rate your views on the statements below on a scale of 1 to 5.
(5=Strongly agree, 4=Agree, 3=Neither agree nor disagree, 2=Disagree, 1=Strongly disagree)
The content met the overall learning objectives of the webinar.
The content met the overall learning objectives of the webinar.
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
The presentations and discussions improved my knowledge on the latest advancements and best practices in DLBCL management and are relevant to my clinical practice.
The presentations and discussions improved my knowledge on the latest advancements and best practices in DLBCL management and are relevant to my clinical practice.
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
3. How likely are you to apply the knowledge and insights gained in your own clinical practice
(10=Extremely likely, 1=Not at all likely)
3. How likely are you to apply the knowledge and insights gained in your own clinical practice? (10=Extremely likely, 1=Not at all likely)
10
9
8
7
6
5
4
3
2
1
10
10
9
9
8
8
7
7
6
6
5
5
4
4
3
3
2
2
1
1
OVERALL EVALUATION AND FUTURE COLLABORATIONS
1. Please rate your overall experience of the webinar.
(5=Very satisfied, 4=Somewhat satisfied, 3=Neither satisfied nor unsatisfied, 2=Somewhat unsatisfied, 1=Very unsatisfied)
Webinar day and time
Webinar day and time
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
Webinar duration
Webinar duration
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
Technical aspects (platform; audio and visual quality)
Technical aspects (platform; audio and visual quality)
5
4
3
2
1
5
5
4
4
3
3
2
2
1
1
2. How likely are you to recommend this event to your colleagues?
(10=Extremely likely, 1=Not at all likely)
2. How likely are you to recommend this event to your colleagues? (10=Extremely likely, 1=Not at all likely)
10
9
8
7
6
5
4
3
2
1
10
10
9
9
8
8
7
7
6
6
5
5
4
4
3
3
2
2
1
1
3. How likely are you to attend future events/activities (e.g., webinars, focus group discussions, chat groups) supported by AbbVie?
(10=Extremely likely, 1=Not at all likely)
3. How likely are you to attend future events/activities (e.g., webinars, focus group discussions, chat groups) supported by AbbVie? (10=Extremely likely, 1=Not at all likely)
10
9
8
7
6
5
4
3
2
1
10
10
9
9
8
8
7
7
6
6
5
5
4
4
3
3
2
2
1
1
4. Please provide your suggestions on enhancing your overall experience to improve our future webinars and events.
4. Please provide your suggestions on enhancing your overall experience to improve our future webinars and events.
Submit
EPCO-MY-00008-E
